Swiss National Bank continued to hold its stake in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 54,700 shares of the biopharmaceutical company’s stock at the end of the second quarter. Swiss National Bank owned about 0.13% of Intra-Cellular Therapies worth $2,123,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Capital Impact Advisors LLC raised its stake in shares of Intra-Cellular Therapies by 292.1% in the first quarter. Capital Impact Advisors LLC now owns 18,088 shares of the biopharmaceutical company’s stock valued at $503,000 after buying an additional 13,475 shares in the last quarter. TIAA CREF Investment Management LLC raised its stake in shares of Intra-Cellular Therapies by 13.8% in the first quarter. TIAA CREF Investment Management LLC now owns 125,515 shares of the biopharmaceutical company’s stock valued at $3,489,000 after buying an additional 15,245 shares in the last quarter. Teachers Advisors Inc. raised its stake in shares of Intra-Cellular Therapies by 7.0% in the first quarter. Teachers Advisors Inc. now owns 60,415 shares of the biopharmaceutical company’s stock valued at $1,680,000 after buying an additional 3,931 shares in the last quarter. BlackRock Inc. raised its stake in shares of Intra-Cellular Therapies by 1.0% in the first quarter. BlackRock Inc. now owns 102,574 shares of the biopharmaceutical company’s stock valued at $2,852,000 after buying an additional 1,048 shares in the last quarter. Finally, BlackRock Group LTD raised its stake in shares of Intra-Cellular Therapies by 10.5% in the first quarter. BlackRock Group LTD now owns 485,807 shares of the biopharmaceutical company’s stock valued at $13,506,000 after buying an additional 46,327 shares in the last quarter. Institutional investors and hedge funds own 70.15% of the company’s stock.

Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) traded down 0.76% during midday trading on Monday, hitting $44.14. The stock had a trading volume of 599,295 shares. The firm’s market capitalization is $1.91 billion. The company’s 50 day moving average price is $41.35 and its 200-day moving average price is $36.40. Intra-Cellular Therapies Inc. has a 1-year low of $22.41 and a 1-year high of $60.79.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.08. The firm earned $0.23 million during the quarter, compared to analyst estimates of $0.02 million. During the same period last year, the firm earned ($0.61) EPS. Intra-Cellular Therapies’s quarterly revenue was up 283.3% on a year-over-year basis. Equities analysts predict that Intra-Cellular Therapies Inc. will post ($3.17) earnings per share for the current year.

Several analysts recently issued reports on ITCI shares. Piper Jaffray Cos. started coverage on Intra-Cellular Therapies in a report on Wednesday, June 1st. They set an “overweight” rating and a $57.00 price objective for the company. Leerink Swann reiterated a “buy” rating on shares of Intra-Cellular Therapies in a report on Wednesday, June 22nd. Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Wednesday, June 29th. Finally, Cowen and Company reiterated a “buy” rating on shares of Intra-Cellular Therapies in a report on Wednesday, June 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $70.25.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

5 Day Chart for NASDAQ:ITCI

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.